MediWound (MDWD) files Form 6-K with Q3 2025 results release

Rhea-AI Filing Summary

MediWound Ltd. submitted a Form 6-K to furnish a press release titled “MediWound Reports Third Quarter 2025 Financial Results and Provides Corporate Update.” The filing notes that the full press release is attached as Exhibit 99.1 and contains the detailed financial and corporate information for the third quarter of 2025.

The company also states that the information in this Form 6-K, including Exhibit 99.1 but excluding quotes from senior management, is incorporated by reference into multiple existing registration statements on Form S-8 and Form F-3. This allows the attached information to be used in connection with those previously filed securities registration documents.

Form 6-K: How Foreign Companies Report to the SEC →

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549
______________________

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16 of the
Securities Exchange Act of 1934

For the month of November 2025

Commission File Number: 001-36349

MediWound Ltd.
(Translation of registrant’s name into English)

42 Hayarkon Street

Yavne, 8122745 Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

EXPLANATORY NOTE

On November 20, 2025, MediWound Ltd. (the “Company”) issued a press release entitled “MediWound Reports Third Quarter 2025 Financial Results and Provides Corporate Update”. A copy of this press release is attached to this Form 6-K as Exhibit 99.1.

The contents of this Report of Foreign Private Issuer on Form 6-K (including the information contained in Exhibit 99.1, but excluding quotes of senior management of the Company) are hereby incorporated by reference into the Company’s Registration Statements on Form S-8 filed with the SEC on April 28, 2014, March 24, 2016, March 19, 2018, March 25, 2019, February 25, 2020, May 15, 2021 August 9, 2022, August 15, 2023, and March 19, 2025 (Registration Nos. No. 333-195517, 333-210375, 333-223767, 333-230487, 333-236635, 333-255784, 333-266697, 333-273997 and 333-285897, respectively) and on Form F-3 filed with the SEC on March 31, 2023,  August 29, 2024 and March 19, 2025 (Registration Nos. 333-268297, 333-281843 and 333-285908, respectively).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: November 20, 2025 MEDIWOUND LTD.   By:      /s/ Hani Luxenburg Name: Hani Luxenburg Title:   Chief Financial Officer

EXHIBIT INDEX

The following exhibit is filed as part of this Form 6-K:

Exhibit Description

99.1 Press release dated November 20, 2025 titled “MediWound Reports Third Quarter 2025 Financial Results and Provides Corporate Update”.

FAQ

What does MediWound (MDWD) disclose in this Form 6-K?

The Form 6-K states that MediWound Ltd. has issued a press release titled “MediWound Reports Third Quarter 2025 Financial Results and Provides Corporate Update,” and that this press release is attached as Exhibit 99.1. The detailed financial and operational information is contained in that exhibit.

How is the attached Q3 2025 press release used in MediWound (MDWD) SEC filings?

The company explains that the contents of this Form 6-K, including Exhibit 99.1 but excluding senior management quotes, are incorporated by reference into its existing registration statements on Form S-8 and Form F-3.

Which MediWound (MDWD) registration statements are affected by this Form 6-K?

The information in this Form 6-K is incorporated into multiple Form S-8 registration statements filed in 2014, 2016, 2018, 2019, 2020, 2021, 2022, 2023, and 2025, as well as into Form F-3 registration statements filed in March 2023, August 2024, and March 2025.

Does this MediWound (MDWD) Form 6-K itself contain detailed financial results?

The text provided indicates that the detailed third quarter 2025 financial results and corporate update are in the attached press release (Exhibit 99.1), rather than in the body of the Form 6-K summary.

Why is MediWound (MDWD) incorporating this Form 6-K into its S-8 and F-3 filings?

By stating that this Form 6-K, including its exhibit, is incorporated by reference into existing S-8 and F-3 registration statements, MediWound ensures that the latest disclosed information, aside from management quotes, forms part of the disclosure record supporting those securities offerings.

What exhibit is included with this MediWound (MDWD) Form 6-K?

The Form 6-K includes an Exhibit Index stating that the press release titled “MediWound Reports Third Quarter 2025 Financial Results and Provides Corporate Update” is filed as Exhibit 99.1.